This company listing is no longer active
MicroPort CardioFlow Medtech Zukünftiges Wachstum
Future Kriterienprüfungen 5/6
MicroPort CardioFlow Medtech is forecast to grow earnings and revenue by 114.6% and 23.5% per annum respectively. EPS is expected to grow by 115.5% per annum. Return on equity is forecast to be 1.4% in 3 years.
Wichtige Informationen
114.6%
Wachstumsrate der Gewinne
115.5%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 39.2% |
| Wachstumsrate der Einnahmen | 23.5% |
| Zukünftige Eigenkapitalrendite | 1.4% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 05 Sep 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 753 | 99 | 8 | N/A | 3 |
| 12/31/2025 | 571 | -27 | -99 | N/A | 3 |
| 12/31/2024 | 456 | -148 | -70 | N/A | 1 |
| 6/30/2024 | 383 | -349 | N/A | N/A | N/A |
| 3/31/2024 | 360 | -410 | N/A | N/A | N/A |
| 12/31/2023 | 336 | -472 | -237 | -207 | N/A |
| 9/30/2023 | 319 | -491 | -250 | -216 | N/A |
| 6/30/2023 | 303 | -511 | -263 | -226 | N/A |
| 3/31/2023 | 277 | -483 | -247 | -204 | N/A |
| 12/31/2022 | 251 | -454 | -232 | -183 | N/A |
| 9/30/2022 | 245 | -345 | -270 | -191 | N/A |
| 6/30/2022 | 239 | -236 | -309 | -199 | N/A |
| 3/31/2022 | 220 | -209 | -290 | -180 | N/A |
| 12/31/2021 | 201 | -183 | -270 | -162 | N/A |
| 9/30/2021 | 176 | -265 | N/A | N/A | N/A |
| 6/30/2021 | 151 | -346 | N/A | N/A | N/A |
| 3/31/2021 | 128 | -372 | N/A | N/A | N/A |
| 12/31/2020 | 104 | -398 | -168 | -110 | N/A |
| 12/31/2019 | 22 | -145 | -191 | -143 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 2160 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Ertrag vs. Markt: 2160 is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hohe Wachstumserträge: 2160 is expected to become profitable in the next 3 years.
Einnahmen vs. Markt: 2160's revenue (23.5% per year) is forecast to grow faster than the Hong Kong market (7.3% per year).
Hohe Wachstumseinnahmen: 2160's revenue (23.5% per year) is forecast to grow faster than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 2160's Return on Equity is forecast to be low in 3 years time (1.4%).